AngioJet Falls Short On Prophylactic Use; Possis Fortifies Current Indication
This article was originally published in The Gray Sheet
Executive Summary
Possis Medical will present an analysis of baseline patient characteristics that may have contributed to adverse AiMI study results at TCT 2004 in Washington, D.C. Sept. 27-Oct. 1
You may also be interested in...
Bayer Builds Cardiovascular Franchise With Possis Purchase
Bayer HealthCare will expand its cardiovascular device offerings by acquiring AngioJet thrombectomy system maker Possis Medical for $361 million under a deal announced Feb. 11
Bayer Builds Cardiovascular Franchise With Possis Purchase
Bayer HealthCare will expand its cardiovascular device offerings by acquiring AngioJet thrombectomy system maker Possis Medical for $361 million under a deal announced Feb. 11
Possis Aims To Reverse AngioJet Losses With JETSTENT Trial
Possis views its upcoming 500-patient JETSTENT trial as the final step in a three-part plan to overcome the damaging results of its 2004 AiMI study and recover lostAngioJet thrombectomy system sales